Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
The plan is to advance innovative therapies to drug-resistant cancers
Subscribe To Our Newsletter & Stay Updated
